Nutra Pharma Corp. (NPHC) Adds More Cobras to its
Post# of 102
Posted On: 03/16/2016 10:01:44 PM
Nutra Pharma Corp. (NPHC) Adds More Cobras to its Milking Farm to Meet Rising Demand from India and China Expansions
Over-the-counter (OTC) pain medications should be the first choice when trying to tolerate chronic pain. Ultra-addictive, narcotic pain medications produced by big pharma companies are so rampant in today’s world. Nutra Pharma Corp. (OTCQB: NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma’s intellectual property portfolio is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
Nutra Pharma’s product pipeline includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company’s Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
One problem with making a pain medication from cobra venom is the supply of cobra venom. Nutra Pharma has completed a series of projects to update and expand the facilities that house the Asian cobras utilized for the production of Nyloxin. Included with these updates was the addition of 100 snakes to the existing milking line to increase venom production in line with upcoming international orders from India and China.
“We are at an amazing inflection point for the Company,” Rik J. Deitsch, Chairman and CEO of Nutra Pharma, stated in a news release. “Over the past few months, we have dramatically reduced costs, paid down debt and recapitalized the share structure of the Company,” he continued. “Now we need to focus on increasing sales for our OTC products, Nyloxin and Pet Pain-Away. This also requires us to scale up our raw material supplies and production facilities. The growth-limiting material for Nutra Pharma is cobra venom, the active ingredient in our OTC products. We need to make sure that we have an adequate supply of validated material to meet our future production needs. With the recently announced expansion into India and China, we realize that we will need to grow exponentially to meet these expected product orders in the coming months. The expansion of the reptile facilities ensures that we can grow apace with the increasing orders.”
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Over-the-counter (OTC) pain medications should be the first choice when trying to tolerate chronic pain. Ultra-addictive, narcotic pain medications produced by big pharma companies are so rampant in today’s world. Nutra Pharma Corp. (OTCQB: NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma’s intellectual property portfolio is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
Nutra Pharma’s product pipeline includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company’s Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
One problem with making a pain medication from cobra venom is the supply of cobra venom. Nutra Pharma has completed a series of projects to update and expand the facilities that house the Asian cobras utilized for the production of Nyloxin. Included with these updates was the addition of 100 snakes to the existing milking line to increase venom production in line with upcoming international orders from India and China.
“We are at an amazing inflection point for the Company,” Rik J. Deitsch, Chairman and CEO of Nutra Pharma, stated in a news release. “Over the past few months, we have dramatically reduced costs, paid down debt and recapitalized the share structure of the Company,” he continued. “Now we need to focus on increasing sales for our OTC products, Nyloxin and Pet Pain-Away. This also requires us to scale up our raw material supplies and production facilities. The growth-limiting material for Nutra Pharma is cobra venom, the active ingredient in our OTC products. We need to make sure that we have an adequate supply of validated material to meet our future production needs. With the recently announced expansion into India and China, we realize that we will need to grow exponentially to meet these expected product orders in the coming months. The expansion of the reptile facilities ensures that we can grow apace with the increasing orders.”
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Nutra Pharma Corp. (NPHC) Stock Research Links
Scroll down for more posts ▼